{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["van Pamelen J"],"funding":["Dutch National MS Foundation"],"pagination":["20552173251370830"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12405697"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["11(3)"],"pubmed_abstract":["<h4>Background</h4>In relapsing-remitting multiple sclerosis (RRMS), the assessment of clinical disease activity can be challenging.<h4>Objectives</h4>To determine the diagnostic potential of serum neurofilament light (sNfL) and glial fibrillary acidic protein (sGFAP) to distinguish a relapse from other causes of deterioration.<h4>Methods</h4>In this multicenter, prospective study, RRMS patients with new neurological symptoms in the last 14 days were followed for 12 weeks. A diagnosis was established by the treating physician or, when in doubt, a panel of experienced neurologists. Blood samples were taken at baseline and week 12.<h4>Results</h4>A total of 65 patients were included. At baseline, patients with a clear relapse had a significantly higher median sNfL (14.6 pg/mL) than those wit"],"journal":["Multiple sclerosis journal - experimental, translational and clinical"],"pubmed_title":["Relapse or no relapse in multiple sclerosis: Can disease activity biomarkers support the clinician?"],"pmcid":["PMC12405697"],"funding_grant_id":["OZ2018-007"],"pubmed_authors":["Arnoldus EPJ","Killestein J","Lissenberg BI","van Pamelen J","van Vliet J","Koel-Simmelink MJA","Visser LH","Teunissen CE","de Beukelaar J"],"additional_accession":[]},"is_claimable":false,"name":"Relapse or no relapse in multiple sclerosis: Can disease activity biomarkers support the clinician?","description":"<h4>Background</h4>In relapsing-remitting multiple sclerosis (RRMS), the assessment of clinical disease activity can be challenging.<h4>Objectives</h4>To determine the diagnostic potential of serum neurofilament light (sNfL) and glial fibrillary acidic protein (sGFAP) to distinguish a relapse from other causes of deterioration.<h4>Methods</h4>In this multicenter, prospective study, RRMS patients with new neurological symptoms in the last 14 days were followed for 12 weeks. A diagnosis was established by the treating physician or, when in doubt, a panel of experienced neurologists. Blood samples were taken at baseline and week 12.<h4>Results</h4>A total of 65 patients were included. At baseline, patients with a clear relapse had a significantly higher median sNfL (14.6 pg/mL) than those wit","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jul-Sep","modification":"2026-05-29T22:02:41.743Z","creation":"2026-04-08T06:13:29.044Z"},"accession":"S-EPMC12405697","cross_references":{"pubmed":["40909760"],"doi":["10.1177/20552173251370830"]}}